Use Of Cannabinoids In The Treatment Of Epilepsy


The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Owners (US)

Information currently unavailable.

CPC Classifications
IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Dec 17, 2015
  • Application: Jun 17, 2015
    US US 201514741829 A
  • Priority: Jun 17, 2014
    GB GB 201410771 A

Sign in to the Lens